Streetbeat News

Products Services

CRWD

CrowdStrike Holdings Inc (NASDAQ:CRWD) is named as the 'Top Pick For 2024' in cybersecurity by Oppenheimer analyst Ittai Kidron, who maintains an Outperform rating and raises the price target from $240 to $300. The company benefits from high cybersecurity spending, attractive cross-sell opportunities with Falcon Data Protection, ARR/NRR expansion, and leveraging partnerships. Despite a strong performance in 2023, further upside is expected in fiscal 2025.

Portfolio Pulse from Priya Nigam

January 05, 2024 | 3:41 pm

NVO

A U.S. study found that Novo Nordisk's drugs Ozempic and Wegovy do not increase the risk of suicidal thoughts. Contrary to prior concerns, the study showed a lower incidence of such thoughts among users compared to other treatments. The study, funded by the U.S. National Institutes of Health and published in 'Nature,' analyzed data from over 1.8 million patients. Semaglutide, the active ingredient in both drugs, was linked to a significantly lower risk of suicidal ideations. Novo Nordisk's stock (NVO) was down 0.60% at $106.99 on the last check Friday.

Portfolio Pulse from Vandana Singh

January 05, 2024 | 3:41 pm

DRMA

Dermata Therapeutics Inc (NASDAQ:DRMA) stock rose after announcing a new patent in Japan for its DMT410 program for hyperhidrosis. The patent strengthens the company's IP and could support further development for additional skin conditions. The company's Spongilla technology enables topical delivery of botulinum toxin, avoiding injections. Phase 1 trials of DMT410 with BOTOX showed promising results for hyperhidrosis and aesthetic skin conditions. DRMA shares surged 31% to 80 cents.

Portfolio Pulse from Vandana Singh

January 05, 2024 | 3:40 pm

CVAC

GSK

CureVac N.V. (NASDAQ:CVAC) shares are rising after the company announced positive interim data from a Phase 2 study of its COVID-19 vaccine candidates developed with GSK Plc (NYSE:GSK). The study showed meaningful immune responses and favorable reactogenicity profiles at all tested doses. The vaccines use CureVac's second-generation mRNA technology and are part of a joint development program with GSK, which also includes a flu vaccine program.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 3:31 pm

AZN

GRCL

AstraZeneca (NASDAQ:AZN) is set to acquire Gracell Biotechnologies Inc. (NASDAQ:GRCL) for up to $1.2 billion, an 86% premium over its pre-announcement share price. The deal offers hope for cash-strapped Chinese biotechs, as Gracell's shares surged 60.3% post-announcement. Gracell, which focuses on CAR-T cell therapy for cancer treatment, has been operating at a loss with its most advanced product still in phase 1 trials. The acquisition by AstraZeneca will bolster its cell therapy capabilities, taking over Gracell's technology and trials. However, the sector faces uncertainty due to an FDA investigation into potential risks associated with CAR-T therapies.

Portfolio Pulse from The Bamboo Works

January 05, 2024 | 3:26 pm

GOOG

GOOGL

A Reddit user used Stability AI's Stable Diffusion to create a realistic image of a non-existent woman with a fake passport, raising concerns about AI's potential to forge identities. The incident reflects growing issues with AI misuse, as seen with Scarlett Johansson's lawsuit and fake images in a New Jersey high school. Google has developed a tool to detect AI-generated photos, aiming to mitigate such risks.

Portfolio Pulse from Rounak Jain

January 05, 2024 | 3:18 pm

LUCY

Innovative Eyewear has entered into a license agreement and reached a settlement regarding several IngenioSpec smart eyewear patents. This agreement resolves previous disputes and grants Innovative Eyewear access to important smart eyewear technology.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:06 pm

INGN

Citron Research has declared Inogen's portable oxygen concentrator (POC) as the best product on the market, based on a comprehensive study by the NCOA involving over 1,000 hours and 600 surveys with expert consultation.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 2:58 pm

F

GM

TM

TSLA

U.S. automakers, including Tesla, General Motors, Toyota, and Ford, have shown strong sales performance in 2023, with GM leading as the top-selling automaker in the U.S. Tesla achieved its target of 1.8 million deliveries, while GM reported its best vehicle sales since 2019. Toyota's U.S. sales rose due to demand for its SUVs and sedans, and Ford's sales increased with pickups and SUVs. GM's total sales were 2.6 million units, a 14.1% increase from the previous year, and its EV sales constituted 2.9% of its total sales. GM aims to boost EV sales with increased production and incentives.

Portfolio Pulse from Upwallstreet

January 05, 2024 | 2:55 pm

DKNG

The arrival of Lionel Messi to Inter Miami has led to a significant increase in betting activity on Major League Soccer, particularly on Inter Miami matches and Messi-related bets. Bet365 reported that betting on Inter Miami was 'exponentially massive' and often increased 'by thousand-fold.' Messi's impact on betting was more significant than on the overall match and other soccer betting markets. DraftKings Inc (NASDAQ:DKNG) also acknowledged Messi's influence, with CEO Jason Robins predicting a big change for MLS due to Messi. Both Bet365 and DraftKings offered boosted bets on Messi and Inter Miami.

Portfolio Pulse from Chris Katje

January 05, 2024 | 2:34 pm